Language

Chinese English

Home page

CPIC 2026 | DRAGONHEART Empowers with Soulful Aesthetics, Co-Creating the Cultural Foundation of China’s New Pharmaceutical Industry

Apr 06,2026

DRAGONHEART has officially become the Cultural Strategic Partner of the 1st China Pharmaceutical Innovation Conference. Liu Dali, Founder of DRAGONHEART and Chairman of the Hong Kong Professional Listing and Overseas Go-Listing Service Alliance, has been invited to serve as Co-Chair of the conference organizing committee.

A+H: Chinese Biotech Accelerates Its “Dual-Listing” Strategy

Apr 06,2026

The tide of "A+H" is rising

Chinese Innovative Drugs Return to the M&A Arena

Apr 05,2026

The tide will rise again in 2026 On March 31, two industry giants simultaneously announced acquisition deals: Eli Lilly agreed to acquire sleep-disorder drug company Centessa Pharmaceuticals for up to $7.8 billion, while Biogen shelled out $5.6 billion to acquire Apellis Pharmaceuticals, a developer of immunology and rare-disease therapeutics.

China’s AI-Driven Pharmaceutical Industry Reveals Its “Weight-Loss Ace”

Apr 03,2026

The Race for the Next “Blockbuster King”

China’s Innovative Drugs Spark a Head-to-Head Trial Boom

Apr 03,2026

Challenging DS-8201

Behind Trump’s 100% Tariffs: China’s New Drugs That Cannot Be Contained

Apr 02,2026

US Imposes Tariffs, China Seeks Premiums

China’s Innovative Drugs Going Global: From “Annual Boom” to “Quarterly Surge”

Apr 01,2026

Q1 2026 Panorama Review: China Innovative Drug BD